NRx Pharmaceuticals, Inc.

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, VRTX has a market cap of 99.4B. Regarding current trading prices, NRXPW is priced at $0.07, while VRTX trades at $387.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas VRTX's P/E ratio is 27.54. In terms of profitability, NRXPW's ROE is +1.13%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, NRXPW is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check VRTX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, REGN has a market cap of 58B. Regarding current trading prices, NRXPW is priced at $0.07, while REGN trades at $556.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas REGN's P/E ratio is 14.02. In terms of profitability, NRXPW's ROE is +1.13%, compared to REGN's ROE of +0.15%. Regarding short-term risk, NRXPW is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check REGN's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ALNY has a market cap of 56.4B. Regarding current trading prices, NRXPW is priced at $0.07, while ALNY trades at $429.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ALNY's P/E ratio is -174.77. In terms of profitability, NRXPW's ROE is +1.13%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, NRXPW is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ALNY's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, NRXPW is priced at $0.07, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas SGEN's P/E ratio is -57.19. In terms of profitability, NRXPW's ROE is +1.13%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, NRXPW is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check SGEN's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ARGX has a market cap of 39B. Regarding current trading prices, NRXPW is priced at $0.07, while ARGX trades at $637.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ARGX's P/E ratio is 32.43. In terms of profitability, NRXPW's ROE is +1.13%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, NRXPW is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ARGX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, BNTX has a market cap of 26.7B. Regarding current trading prices, NRXPW is priced at $0.07, while BNTX trades at $111.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas BNTX's P/E ratio is -66.87. In terms of profitability, NRXPW's ROE is +1.13%, compared to BNTX's ROE of -0.02%. Regarding short-term risk, NRXPW is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check BNTX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, NRXPW is priced at $0.07, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas BGNE's P/E ratio is -22.55. In terms of profitability, NRXPW's ROE is +1.13%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, NRXPW is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check BGNE's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, SMMT has a market cap of 19.1B. Regarding current trading prices, NRXPW is priced at $0.07, while SMMT trades at $25.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas SMMT's P/E ratio is -75.54. In terms of profitability, NRXPW's ROE is +1.13%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, NRXPW is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check SMMT's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, NRXPW is priced at $0.07, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, NRXPW's ROE is +1.13%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, NRXPW is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check DNA-WT's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, INCY has a market cap of 15.9B. Regarding current trading prices, NRXPW is priced at $0.07, while INCY trades at $81.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas INCY's P/E ratio is 19.29. In terms of profitability, NRXPW's ROE is +1.13%, compared to INCY's ROE of +0.34%. Regarding short-term risk, NRXPW is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check INCY's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, RPRX has a market cap of 15.1B. Regarding current trading prices, NRXPW is priced at $0.07, while RPRX trades at $35.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas RPRX's P/E ratio is 15.66. In terms of profitability, NRXPW's ROE is +1.13%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, NRXPW is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check RPRX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, GMAB has a market cap of 13.8B. Regarding current trading prices, NRXPW is priced at $0.07, while GMAB trades at $21.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas GMAB's P/E ratio is 11.33. In terms of profitability, NRXPW's ROE is +1.13%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, NRXPW is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check GMAB's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, UTHR has a market cap of 13.6B. Regarding current trading prices, NRXPW is priced at $0.07, while UTHR trades at $301.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas UTHR's P/E ratio is 11.76. In terms of profitability, NRXPW's ROE is +1.13%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, NRXPW is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check UTHR's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, NRXPW is priced at $0.07, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas KRTX's P/E ratio is -28.09. In terms of profitability, NRXPW's ROE is +1.13%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, NRXPW is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check KRTX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ASND has a market cap of 11.9B. Regarding current trading prices, NRXPW is priced at $0.07, while ASND trades at $195.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ASND's P/E ratio is -37.01. In terms of profitability, NRXPW's ROE is +1.13%, compared to ASND's ROE of +1.91%. Regarding short-term risk, NRXPW is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ASND's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, NRXPW is priced at $0.07, while BMRN trades at $56.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas BMRN's P/E ratio is 16.77. In terms of profitability, NRXPW's ROE is +1.13%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, NRXPW is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check BMRN's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, EXEL has a market cap of 10.2B. Regarding current trading prices, NRXPW is priced at $0.07, while EXEL trades at $37.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas EXEL's P/E ratio is 18.25. In terms of profitability, NRXPW's ROE is +1.13%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, NRXPW is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check EXEL's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, MRNA has a market cap of 10B. Regarding current trading prices, NRXPW is priced at $0.07, while MRNA trades at $25.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas MRNA's P/E ratio is -3.42. In terms of profitability, NRXPW's ROE is +1.13%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, NRXPW is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check MRNA's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, NRXPW is priced at $0.07, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas RXDX's P/E ratio is -56.47. In terms of profitability, NRXPW's ROE is +1.13%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, NRXPW is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check RXDX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, BBIO has a market cap of 9.4B. Regarding current trading prices, NRXPW is priced at $0.07, while BBIO trades at $49.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas BBIO's P/E ratio is -11.89. In terms of profitability, NRXPW's ROE is +1.13%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, NRXPW is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check BBIO's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, NRXPW is priced at $0.07, while VRNA trades at $105.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas VRNA's P/E ratio is -101.14. In terms of profitability, NRXPW's ROE is +1.13%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, NRXPW is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check VRNA's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, NRXPW is priced at $0.07, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas IMGN's P/E ratio is -111.55. In terms of profitability, NRXPW's ROE is +1.13%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, NRXPW is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check IMGN's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, NRXPW is priced at $0.07, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas BPMC's P/E ratio is -51.58. In terms of profitability, NRXPW's ROE is +1.13%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, NRXPW is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check BPMC's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, TECH has a market cap of 8.3B. Regarding current trading prices, NRXPW is priced at $0.07, while TECH trades at $52.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas TECH's P/E ratio is 114.85. In terms of profitability, NRXPW's ROE is +1.13%, compared to TECH's ROE of +0.06%. Regarding short-term risk, NRXPW is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check TECH's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, NRXPW is priced at $0.07, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas CERE's P/E ratio is -16.47. In terms of profitability, NRXPW's ROE is +1.13%, compared to CERE's ROE of -0.72%. Regarding short-term risk, NRXPW is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check CERE's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, MDGL has a market cap of 8B. Regarding current trading prices, NRXPW is priced at $0.07, while MDGL trades at $359.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas MDGL's P/E ratio is -28.38. In terms of profitability, NRXPW's ROE is +1.13%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, NRXPW is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check MDGL's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, NRXPW is priced at $0.07, while ROIV trades at $11.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ROIV's P/E ratio is -10.61. In terms of profitability, NRXPW's ROE is +1.13%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, NRXPW is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ROIV's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, NRXPW is priced at $0.07, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, NRXPW's ROE is +1.13%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, NRXPW is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ROIVW's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, CORT has a market cap of 7.8B. Regarding current trading prices, NRXPW is priced at $0.07, while CORT trades at $73.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas CORT's P/E ratio is 65.71. In terms of profitability, NRXPW's ROE is +1.13%, compared to CORT's ROE of +0.20%. Regarding short-term risk, NRXPW is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check CORT's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, HALO has a market cap of 7.5B. Regarding current trading prices, NRXPW is priced at $0.07, while HALO trades at $64.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas HALO's P/E ratio is 14.65. In terms of profitability, NRXPW's ROE is +1.13%, compared to HALO's ROE of +1.37%. Regarding short-term risk, NRXPW is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check HALO's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, JAZZ has a market cap of 6.9B. Regarding current trading prices, NRXPW is priced at $0.07, while JAZZ trades at $113.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas JAZZ's P/E ratio is -16.24. In terms of profitability, NRXPW's ROE is +1.13%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, NRXPW is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check JAZZ's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, IONS has a market cap of 6.6B. Regarding current trading prices, NRXPW is priced at $0.07, while IONS trades at $41.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas IONS's P/E ratio is -23.53. In terms of profitability, NRXPW's ROE is +1.13%, compared to IONS's ROE of -0.45%. Regarding short-term risk, NRXPW is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check IONS's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, RVMD has a market cap of 6.6B. Regarding current trading prices, NRXPW is priced at $0.07, while RVMD trades at $35.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas RVMD's P/E ratio is -7.80. In terms of profitability, NRXPW's ROE is +1.13%, compared to RVMD's ROE of -0.39%. Regarding short-term risk, NRXPW is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check RVMD's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, NRXPW is priced at $0.07, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas RETA's P/E ratio is -66.29. In terms of profitability, NRXPW's ROE is +1.13%, compared to RETA's ROE of +0.47%. Regarding short-term risk, NRXPW is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check RETA's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, NRXPW is priced at $0.07, while RYTM trades at $96.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas RYTM's P/E ratio is -32.05. In terms of profitability, NRXPW's ROE is +1.13%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, NRXPW is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check RYTM's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, RNA has a market cap of 5.9B. Regarding current trading prices, NRXPW is priced at $0.07, while RNA trades at $46.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas RNA's P/E ratio is -12.99. In terms of profitability, NRXPW's ROE is +1.13%, compared to RNA's ROE of -0.33%. Regarding short-term risk, NRXPW is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check RNA's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, NRXPW is priced at $0.07, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, NRXPW's ROE is +1.13%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, NRXPW is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ABCM's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, NRXPW is priced at $0.07, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ISEE's P/E ratio is -22.44. In terms of profitability, NRXPW's ROE is +1.13%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, NRXPW is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ISEE's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, NUVL has a market cap of 5.5B. Regarding current trading prices, NRXPW is priced at $0.07, while NUVL trades at $76.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas NUVL's P/E ratio is -15.57. In terms of profitability, NRXPW's ROE is +1.13%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, NRXPW is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check NUVL's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ABVX has a market cap of 5.4B. Regarding current trading prices, NRXPW is priced at $0.07, while ABVX trades at $71.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ABVX's P/E ratio is -20.90. In terms of profitability, NRXPW's ROE is +1.13%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, NRXPW is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ABVX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, AXSM has a market cap of 5.3B. Regarding current trading prices, NRXPW is priced at $0.07, while AXSM trades at $105.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas AXSM's P/E ratio is -20.80. In terms of profitability, NRXPW's ROE is +1.13%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, NRXPW is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check AXSM's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, NRXPW is priced at $0.07, while CRSP trades at $56.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas CRSP's P/E ratio is -10.48. In terms of profitability, NRXPW's ROE is +1.13%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, NRXPW is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check CRSP's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, MRUS has a market cap of 4.8B. Regarding current trading prices, NRXPW is priced at $0.07, while MRUS trades at $63.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas MRUS's P/E ratio is -11.43. In terms of profitability, NRXPW's ROE is +1.13%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, NRXPW is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check MRUS's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ALKS has a market cap of 4.5B. Regarding current trading prices, NRXPW is priced at $0.07, while ALKS trades at $27.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ALKS's P/E ratio is 13.25. In terms of profitability, NRXPW's ROE is +1.13%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, NRXPW is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ALKS's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, VKTX has a market cap of 4.5B. Regarding current trading prices, NRXPW is priced at $0.07, while VKTX trades at $39.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas VKTX's P/E ratio is -25.88. In terms of profitability, NRXPW's ROE is +1.13%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, NRXPW is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check VKTX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, NRXPW is priced at $0.07, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ALPN's P/E ratio is -101.52. In terms of profitability, NRXPW's ROE is +1.13%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, NRXPW is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ALPN's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, SLNO has a market cap of 4.4B. Regarding current trading prices, NRXPW is priced at $0.07, while SLNO trades at $83.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas SLNO's P/E ratio is -19.75. In terms of profitability, NRXPW's ROE is +1.13%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, NRXPW is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check SLNO's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, TGTX has a market cap of 4.3B. Regarding current trading prices, NRXPW is priced at $0.07, while TGTX trades at $27.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas TGTX's P/E ratio is 71.37. In terms of profitability, NRXPW's ROE is +1.13%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, NRXPW is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check TGTX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, NRXPW is priced at $0.07, while ACAD trades at $25.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ACAD's P/E ratio is 19.14. In terms of profitability, NRXPW's ROE is +1.13%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, NRXPW is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ACAD's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, NRXPW is priced at $0.07, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas OPT's P/E ratio is -1.52. In terms of profitability, NRXPW's ROE is +1.13%, compared to OPT's ROE of +2.60%. Regarding short-term risk, NRXPW is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check OPT's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, KRYS has a market cap of 4.2B. Regarding current trading prices, NRXPW is priced at $0.07, while KRYS trades at $143.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas KRYS's P/E ratio is 29.19. In terms of profitability, NRXPW's ROE is +1.13%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, NRXPW is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check KRYS's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, NRXPW is priced at $0.07, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas MRTX's P/E ratio is -4.82. In terms of profitability, NRXPW's ROE is +1.13%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, NRXPW is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check MRTX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, CYTK has a market cap of 4.1B. Regarding current trading prices, NRXPW is priced at $0.07, while CYTK trades at $34.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas CYTK's P/E ratio is -6.70. In terms of profitability, NRXPW's ROE is +1.13%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, NRXPW is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check CYTK's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ACLX has a market cap of 4B. Regarding current trading prices, NRXPW is priced at $0.07, while ACLX trades at $72.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ACLX's P/E ratio is -21.27. In terms of profitability, NRXPW's ROE is +1.13%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, NRXPW is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ACLX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ADMA has a market cap of 4B. Regarding current trading prices, NRXPW is priced at $0.07, while ADMA trades at $16.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ADMA's P/E ratio is 19.72. In terms of profitability, NRXPW's ROE is +1.13%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, NRXPW is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ADMA's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, PCVX has a market cap of 4B. Regarding current trading prices, NRXPW is priced at $0.07, while PCVX trades at $30.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas PCVX's P/E ratio is -7.41. In terms of profitability, NRXPW's ROE is +1.13%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, NRXPW is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check PCVX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, AKRO has a market cap of 3.8B. Regarding current trading prices, NRXPW is priced at $0.07, while AKRO trades at $48.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas AKRO's P/E ratio is -12.61. In terms of profitability, NRXPW's ROE is +1.13%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, NRXPW is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check AKRO's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ZLAB has a market cap of 3.8B. Regarding current trading prices, NRXPW is priced at $0.07, while ZLAB trades at $34.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ZLAB's P/E ratio is -17.15. In terms of profitability, NRXPW's ROE is +1.13%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, NRXPW is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ZLAB's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, NRXPW is priced at $0.07, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas RYZB's P/E ratio is -57.86. In terms of profitability, NRXPW's ROE is +1.13%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, NRXPW is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check RYZB's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, NRXPW is priced at $0.07, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas CBAY's P/E ratio is -32.81. In terms of profitability, NRXPW's ROE is +1.13%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, NRXPW is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check CBAY's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, AAPG has a market cap of 3.7B. Regarding current trading prices, NRXPW is priced at $0.07, while AAPG trades at $40.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas AAPG's P/E ratio is -54.12. In terms of profitability, NRXPW's ROE is +1.13%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, NRXPW is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check AAPG's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, NRXPW is priced at $0.07, while TLX trades at $10.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas TLX's P/E ratio is 120.22. In terms of profitability, NRXPW's ROE is +1.13%, compared to TLX's ROE of +0.10%. Regarding short-term risk, NRXPW is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check TLX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, PTCT has a market cap of 3.6B. Regarding current trading prices, NRXPW is priced at $0.07, while PTCT trades at $45.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas PTCT's P/E ratio is 6.42. In terms of profitability, NRXPW's ROE is +1.13%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, NRXPW is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check PTCT's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, NRXPW is priced at $0.07, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas SWTX's P/E ratio is -13.78. In terms of profitability, NRXPW's ROE is +1.13%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, NRXPW is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check SWTX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, NRXPW is priced at $0.07, while MLTX trades at $54.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas MLTX's P/E ratio is -19.66. In terms of profitability, NRXPW's ROE is +1.13%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, NRXPW is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check MLTX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, NRXPW is priced at $0.07, while LEGN trades at $36.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas LEGN's P/E ratio is -31.35. In terms of profitability, NRXPW's ROE is +1.13%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, NRXPW is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check LEGN's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, PTGX has a market cap of 3.4B. Regarding current trading prices, NRXPW is priced at $0.07, while PTGX trades at $54.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas PTGX's P/E ratio is 74.70. In terms of profitability, NRXPW's ROE is +1.13%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, NRXPW is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check PTGX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, MIRM has a market cap of 3.3B. Regarding current trading prices, NRXPW is priced at $0.07, while MIRM trades at $64.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas MIRM's P/E ratio is -53.49. In terms of profitability, NRXPW's ROE is +1.13%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, NRXPW is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check MIRM's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, MTSR has a market cap of 3.2B. Regarding current trading prices, NRXPW is priced at $0.07, while MTSR trades at $30.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas MTSR's P/E ratio is -10.47. In terms of profitability, NRXPW's ROE is +1.13%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, NRXPW is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check MTSR's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, SRRK has a market cap of 3.1B. Regarding current trading prices, NRXPW is priced at $0.07, while SRRK trades at $32.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas SRRK's P/E ratio is -11.03. In terms of profitability, NRXPW's ROE is +1.13%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, NRXPW is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check SRRK's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, APLS has a market cap of 3B. Regarding current trading prices, NRXPW is priced at $0.07, while APLS trades at $23.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas APLS's P/E ratio is -13.06. In terms of profitability, NRXPW's ROE is +1.13%, compared to APLS's ROE of -1.16%. Regarding short-term risk, NRXPW is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check APLS's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, LGND has a market cap of 3B. Regarding current trading prices, NRXPW is priced at $0.07, while LGND trades at $152.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas LGND's P/E ratio is -37.89. In terms of profitability, NRXPW's ROE is +1.13%, compared to LGND's ROE of -0.09%. Regarding short-term risk, NRXPW is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check LGND's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, NRXPW is priced at $0.07, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas MORF's P/E ratio is -14.88. In terms of profitability, NRXPW's ROE is +1.13%, compared to MORF's ROE of -0.16%. Regarding short-term risk, NRXPW is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check MORF's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, NRXPW is priced at $0.07, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas MOR's P/E ratio is -12.64. In terms of profitability, NRXPW's ROE is +1.13%, compared to MOR's ROE of -1.84%. Regarding short-term risk, NRXPW is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check MOR's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, NAMS has a market cap of 2.8B. Regarding current trading prices, NRXPW is priced at $0.07, while NAMS trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas NAMS's P/E ratio is -15.72. In terms of profitability, NRXPW's ROE is +1.13%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, NRXPW is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check NAMS's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, KYMR has a market cap of 2.8B. Regarding current trading prices, NRXPW is priced at $0.07, while KYMR trades at $39.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas KYMR's P/E ratio is -11.42. In terms of profitability, NRXPW's ROE is +1.13%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, NRXPW is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check KYMR's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, XENE has a market cap of 2.8B. Regarding current trading prices, NRXPW is priced at $0.07, while XENE trades at $35.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas XENE's P/E ratio is -11.18. In terms of profitability, NRXPW's ROE is +1.13%, compared to XENE's ROE of -0.32%. Regarding short-term risk, NRXPW is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check XENE's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, RARE has a market cap of 2.7B. Regarding current trading prices, NRXPW is priced at $0.07, while RARE trades at $28.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas RARE's P/E ratio is -5.13. In terms of profitability, NRXPW's ROE is +1.13%, compared to RARE's ROE of -2.37%. Regarding short-term risk, NRXPW is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check RARE's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, NRXPW is priced at $0.07, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas KDNY's P/E ratio is -12.47. In terms of profitability, NRXPW's ROE is +1.13%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, NRXPW is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check KDNY's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, CRNX has a market cap of 2.7B. Regarding current trading prices, NRXPW is priced at $0.07, while CRNX trades at $28.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas CRNX's P/E ratio is -6.95. In terms of profitability, NRXPW's ROE is +1.13%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, NRXPW is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check CRNX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, NRXPW is priced at $0.07, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas MYOV's P/E ratio is -14.05. In terms of profitability, NRXPW's ROE is +1.13%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, NRXPW is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check MYOV's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, IMVT has a market cap of 2.6B. Regarding current trading prices, NRXPW is priced at $0.07, while IMVT trades at $15.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas IMVT's P/E ratio is -5.57. In terms of profitability, NRXPW's ROE is +1.13%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, NRXPW is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check IMVT's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, NRXPW is priced at $0.07, while CPRX trades at $20.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas CPRX's P/E ratio is 12.33. In terms of profitability, NRXPW's ROE is +1.13%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, NRXPW is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check CPRX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, ARWR has a market cap of 2.5B. Regarding current trading prices, NRXPW is priced at $0.07, while ARWR trades at $17.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas ARWR's P/E ratio is -14.83. In terms of profitability, NRXPW's ROE is +1.13%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, NRXPW is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check ARWR's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, KNSA has a market cap of 2.4B. Regarding current trading prices, NRXPW is priced at $0.07, while KNSA trades at $32.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas KNSA's P/E ratio is 655.60. In terms of profitability, NRXPW's ROE is +1.13%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, NRXPW is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check KNSA's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, NRXPW is priced at $0.07, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas PRVB's P/E ratio is -16.43. In terms of profitability, NRXPW's ROE is +1.13%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, NRXPW is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check PRVB's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, BLTE has a market cap of 2.4B. Regarding current trading prices, NRXPW is priced at $0.07, while BLTE trades at $72.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas BLTE's P/E ratio is -46.92. In terms of profitability, NRXPW's ROE is +1.13%, compared to BLTE's ROE of -0.37%. Regarding short-term risk, NRXPW is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check BLTE's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, NRXPW is priced at $0.07, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas LBPH's P/E ratio is -26.66. In terms of profitability, NRXPW's ROE is +1.13%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, NRXPW is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check LBPH's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, IBRX has a market cap of 2.3B. Regarding current trading prices, NRXPW is priced at $0.07, while IBRX trades at $2.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas IBRX's P/E ratio is -5.15. In terms of profitability, NRXPW's ROE is +1.13%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, NRXPW is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check IBRX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, RXRX has a market cap of 2.3B. Regarding current trading prices, NRXPW is priced at $0.07, while RXRX trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas RXRX's P/E ratio is -2.99. In terms of profitability, NRXPW's ROE is +1.13%, compared to RXRX's ROE of -0.76%. Regarding short-term risk, NRXPW is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check RXRX's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, NRXPW is priced at $0.07, while CNTA trades at $17.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas CNTA's P/E ratio is -9.10. In terms of profitability, NRXPW's ROE is +1.13%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, NRXPW is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check CNTA's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, NRXPW is priced at $0.07, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas DICE's P/E ratio is -21.91. In terms of profitability, NRXPW's ROE is +1.13%, compared to DICE's ROE of +0.56%. Regarding short-term risk, NRXPW is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check DICE's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, VCYT has a market cap of 2.3B. Regarding current trading prices, NRXPW is priced at $0.07, while VCYT trades at $28.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas VCYT's P/E ratio is 84.62. In terms of profitability, NRXPW's ROE is +1.13%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, NRXPW is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check VCYT's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, NRXPW is priced at $0.07, while APGE trades at $36.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas APGE's P/E ratio is -8.86. In terms of profitability, NRXPW's ROE is +1.13%, compared to APGE's ROE of -0.23%. Regarding short-term risk, NRXPW is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check APGE's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, OCUL has a market cap of 2.2B. Regarding current trading prices, NRXPW is priced at $0.07, while OCUL trades at $12.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas OCUL's P/E ratio is -9.90. In terms of profitability, NRXPW's ROE is +1.13%, compared to OCUL's ROE of -0.70%. Regarding short-term risk, NRXPW is more volatile compared to OCUL. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check OCUL's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, TARS has a market cap of 2.2B. Regarding current trading prices, NRXPW is priced at $0.07, while TARS trades at $51.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas TARS's P/E ratio is -22.43. In terms of profitability, NRXPW's ROE is +1.13%, compared to TARS's ROE of -0.32%. Regarding short-term risk, NRXPW is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check TARS's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, FOLD has a market cap of 2.2B. Regarding current trading prices, NRXPW is priced at $0.07, while FOLD trades at $6.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas FOLD's P/E ratio is -58.17. In terms of profitability, NRXPW's ROE is +1.13%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, NRXPW is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check FOLD's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, NRXPW is priced at $0.07, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas CALT's P/E ratio is -22.73. In terms of profitability, NRXPW's ROE is +1.13%, compared to CALT's ROE of -1.67%. Regarding short-term risk, NRXPW is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check CALT's competition here

NRXPW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NRXPW stands at 50.6M. In comparison, GLPG has a market cap of 2.1B. Regarding current trading prices, NRXPW is priced at $0.07, while GLPG trades at $31.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NRXPW currently has a P/E ratio of -0.01, whereas GLPG's P/E ratio is -6.20. In terms of profitability, NRXPW's ROE is +1.13%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, NRXPW is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for NRXPW.Check GLPG's competition here